Serum procalcitonin as a diagnostic tool of bacteremia 英文参考文献.docVIP

Critical Care 2010, Volume 14 Suppl 2 /supplements/14/S2 MEETING ABSTR AC TS Sepsis 2010 Paris, France. 1–3 September 2010 Published: 1 September 2010 P1 Epidemiology of sepsis in pediatrics: ? rst Colombian multicenter pilot survey J Camilo Jaramillo-Bustamante , A Marín-Agudelo , M Fernández-Laverde , 1 1 1 dose-dependently associated with increased renal failure, tissue storage with organ failure, and increased long-term mortality. There are other safety concerns with regard to coagulopathy, pruritus, and mortality. However, third-generation HES 130/0.4 is considered to have an improved risk pro? le. Therefore, we wanted to assess whether published studies on HES 130/0.4 resuscitation are su? ciently well designed to draw conclusions about the safety of this compound. J Bare?o-Silva 2 1 CES University, Pediatric Intensive Care Program, Medellin, Colombia; CES University, Epidemiology and Bio-statistic Research Group, Medellin, 2 Colombia Critical Care 2010, 14(Suppl 2):P1 (doi: 10.1186/cc9104) Methods We derived clinically relevant outcome parameters to analyze safety outcomes from the literature and provided exemplary power calculations. Randomized controlled trials (RCT) on ? uid resuscitation with HES 130/0.4 were systematically searched and analyzed for clinical condition, sample size, study duration, cumulative dose, control ? uids, endpoints, and colloid– crystalloid volume ratios in studies with a goal-directed ? uid regimen. Due to the heterogeneity of included studies, all analyses were descriptive (SPSS 17.0). Results A total of 56 RCTs were included. Only two studies included severe sepsis patients, 80% were from the elective surgical setting and one study from the emergency surgical setting. In general, studies were underpowered (median sample size 25